Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
PR Newswire; Friday December 19, 11:56 am EST
While conducting two Phase 3 clinical trials in HIV and hepatitis C infected patients respectively, the Company found that many patients are co-infected with both HIV and hepatitis C viruses. According to Dr. Andrew Talal of The Aaron Diamond AIDS Research Center in New York, one of the centers participating in this trial, ``It is estimated that approximately 10% of the HIV-infected population are co-infected with hepatitis C virus.'' This new trial will study the potential use of a single drug, ALFERON N Injection, to treat both the HIV and hepatitis C viruses simultaneously.
Two different groups of patients with chronic hepatitis C will be studied. One group will have significant HIV viral levels and the second will have low or undetectable levels of HIV. These two groups will be treated with ALFERON N Injection for 24 weeks. The patient's HCV and HIV viral levels will be evaluated throughout the treatment in order to measure the inhibitory effect of ALFERON N Injection on the replication of each virus. The patients will also be followed for an additional 24 weeks after treatment in order to evaluate the durability of any therapeutic benefit observed.
Interferon Sciences, Inc. is a biopharmaceutical company engaged in the manufacture and sale of pharmaceutical products based on its highly purified, natural-source, multispecies alpha interferon. The Company's ALFERON N Injection (Interferon Alfa-n3) product has been approved by the United States Food and Drug Administration for the treatment of certain types of genital warts, and is being studied for potential use in other indications. The Company also has other natural-source alpha interferon formulations in various stages of development for the potential treatment of viral and immune system diseases.
Interferon Sciences' press releases are posted on the Company's website located at http://www.interferonsciences.com. They are also available by facsimile 24 hours per day at no charge by calling PR Newswire's Company News On-Call at 800-758-5804, ext. 445138.
The forward-looking statements contained herein reflect ISI management's current views with respect to future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in the forward- looking statements, all of which are difficult to predict and many of which are beyond the control of ISI, including, but not limited to, those risks and uncertainties detailed in ISI's periodic reports and registration statements filed with the Securities and Exchange Commission.
SOURCE: Interferon Sciences, Inc.
Copyright (c) 1997/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
971219
PR971217
Copyright © 1997 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .